Detalhe da pesquisa
1.
Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
Mov Disord
; 39(5): 863-875, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38487964
2.
Patient and Family Outcomes of Community Neurologist Palliative Education and Telehealth Support in Parkinson Disease.
JAMA Neurol
; 81(1): 39-49, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37955923
3.
Assessing the state of care for Huntington disease in the United States: Results from a survey of practices treating Huntington disease patients.
Clin Park Relat Disord
; 7: 100165, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36262527
4.
Natural History of Friedreich's Ataxia: Heterogeneity of Neurological Progression and Consequences for Clinical Trial Design.
Neurology
; 2022 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35817567
5.
Scoliosis in Friedreich's ataxia: longitudinal characterization in a large heterogeneous cohort.
Ann Clin Transl Neurol
; 8(6): 1239-1250, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33949801
6.
Complementary Therapies in Parkinson Disease: a Review of Acupuncture, Tai Chi, Qi Gong, Yoga, and Cannabis.
Neurotherapeutics
; 17(4): 1434-1455, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32785848
7.
Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study.
Cannabis Cannabinoid Res
; 5(4): 326-336, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33381646
8.
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.
J Clin Med
; 9(11)2020 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33207828
9.
Movement disorders associated with aripiprazole use: a case series.
Int J Neurosci
; 119(12): 2274-9, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19916856
10.
Novel clinical features of glycine receptor antibody syndrome: A series of 17 cases.
Neurol Neuroimmunol Neuroinflamm
; 6(5): e592, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31355325
11.
Optimizing bioavailability in the treatment of Parkinson's disease.
Neuropharmacology
; 53(7): 791-800, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17936857
12.
Valbenazine for the treatment of tardive dyskinesia.
Expert Opin Pharmacother
; 18(12): 1279-1287, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28699794
13.
Subacute Progressive Imbalance and Jaw Movements Due to Kelch-Like Protein-11 Rhombencephalitis.
Mov Disord Clin Pract
; 9(Suppl 2): S26-S28, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36118513
14.
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.
Neurology
; 88(2): 152-159, 2017 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27913695
15.
Carbidopa levodopa enteral suspension.
Expert Opin Pharmacother
; 16(18): 2807-17, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26595228
16.
Reliability of measurements of patient health status: a comparison of physician, patient, and caregiver ratings.
Parkinsonism Relat Disord
; 8(3): 187-92, 2002 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12039430
17.
Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
Neurologist
; 17(6): 318-24, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22045282
18.
Examination of the UPDRS bradykinesia subscale: equivalence, reliability and validity.
J Parkinsons Dis
; 1(3): 253-8, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-23939305
19.
Levodopa/carbidopa/entacapone in Parkinson's disease.
Expert Rev Neurother
; 9(7): 929-40, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19589043
20.
MS vs. HD: can white matter and subcortical gray matter pathology be distinguished neuropsychologically?
J Clin Exp Neuropsychol
; 29(2): 142-54, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17365249